Musculoskeletal Tissue Engineering

RÀFOLS-MITJANS A, ROIG-MOLINA A, BELTRAMONE S, VIVES J*, BATLLE-MORERA L
Human Wharton’s jelly-derived mesenchymal stromal cells promote bone formation in immunodeficient mice when administered into a bone microenvironment.
J Transl Med 21, 802.
DOI: 10.1186/s12967-023-04672-9.
IF: 8.440

LÓPEZ-FERNÁNDEZ A, CODINACH M, COCA MI, PRAT-VIDAL C, CASTAÑO J, TORRENTS S, ARAN G, RODRÍGUEZ L, QUEROL S, VIVES J* (2023):
Comparability exercise of critical quality attributes of clinical grade human Mesenchymal Stromal Cells from the Wharton’s jelly: single-use stirred tank bioreactors vs. planar culture systems.
Cytotherapy. 2023 Sep 16:S1465-3249(23)01039-3.
DOI: 10.1016/j.jcyt.2023.08.008.
IF: 6.196

DELGADILLO J, KERKELÄ E, WATERS A, VAN DEN AKKER E, LECHANTEUR C, BAUDOUX E, GARDINER N, DE VOS J, VIVES J* (2023):
A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe.
Cytotherapy 25, 1259-1264.
DOI: 10.1016/j.jcyt.2023.08.001
IF: 6.196

VIVES J, SÁNCHEZ-GUIJO F, GNECCHI M, ZWAGINGA JJ (2023):
Cell and Gene Therapy Workforce Development: The Role of the International Society for Cell & Gene Therapy (ISCT) in the Creation of a Sustainable and Skilled Workforce in Europe.
Cytotherapy 25 (10), 1033-1036.
DOI: 10.1016/j.jcyt.2023.06.006. PMID: 37498257
IF: 6.196

GRAU-VORSTER M, TORRENTS S, VIVES J* (2023):
Chapter 3. Potency assays: the “bugaboo” of stem cell therapy. In: Potency assays for stem cell advanced therapy medicinal products (ed. Burns JS)
Adv Exp Med Biol 1420:29-38.
DOI: 10.1007/978-3-031-30040-0_3.
IF: 3.650